📊 HSCSW Key Takeaways
Is HeartSciences Inc. (HSCSW) a Good Investment?
HeartSciences exhibits severe financial distress with revenue collapsed to $4.3K (down 76.6% YoY) while burning $5.8M annually in operating losses, creating an unsustainable burn rate. With $3.4M in cash against -$5.8M annual operating cash flow, the company has approximately 7 months of runway without a dramatic operational turnaround. The combination of near-zero revenue, massive losses, negative returns on capital, and accelerating cash depletion indicates high bankruptcy risk.
HeartSciences shows negligible revenue with extremely negative operating and net margins, indicating no current operating leverage. Cash burn is heavy relative to the $3.4M cash balance and modest liquidity, pointing to near‑term financing needs. While debt-free with positive gross margin on minimal sales, fundamentals do not demonstrate sustainable growth or scale.
Why Buy HeartSciences Inc. Stock? HSCSW Key Strengths
- Maintains $3.4M cash position representing 45% of total assets
- Zero long-term debt burden with 0.00x debt-to-equity ratio
- Positive 59.1% gross margin indicates product has potential value if scalable
- Debt-free balance sheet (0.00x D/E)
- Positive gross margin indicating potential unit economics if scaled
- Low capital intensity (minimal capex)
HSCSW Stock Risks: HeartSciences Inc. Investment Risks
- Revenue essentially zero at $4.3K with -76.6% YoY decline indicates business collapse
- Operating cash flow of -$5.8M annually creates ~7 month cash runway at current burn rate
- Operating loss of -$5.9M on minimal revenue reflects severe operational inefficiency and inability to scale
- Negative ROE (-241%) and ROA (-84.6%) demonstrate destruction of shareholder capital
- No meaningful path to profitability visible with current revenue base
- Going-concern risk from sustained negative FCF and thin liquidity
- Dilution risk due to likely capital raises to fund operations
- Commercialization and adoption risk given near-zero revenue
Key Metrics to Watch
- Quarterly revenue trajectory and any evidence of stabilization or rebound
- Monthly cash burn rate and updated runway estimation
- Operating cash flow sign and magnitude - must improve to positive or funding required
- Quarterly revenue growth and gross margin
- Operating cash burn and cash balance/runway
HeartSciences Inc. (HSCSW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
HeartSciences Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
HSCSW Profit Margin, ROE & Profitability Analysis
HSCSW vs Healthcare Sector: How HeartSciences Inc. Compares
How HeartSciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HeartSciences Inc. Stock Overvalued? HSCSW Valuation Analysis 2026
Based on fundamental analysis, HeartSciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HeartSciences Inc. Balance Sheet: HSCSW Debt, Cash & Liquidity
HSCSW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: HeartSciences Inc.'s revenue has grown significantly by 29% over the 5-year period, indicating strong business expansion. The most recent EPS of $-18.74 indicates the company is currently unprofitable.
HSCSW Revenue Growth, EPS Growth & YoY Performance
HSCSW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | N/A | -$2.0M | N/A |
| Q3 2025 | $14.7K | -$1.6M | $-2.57 |
| Q2 2025 | $2.4K | -$1.7M | $-0.85 |
| Q1 2025 | $1.9K | -$1.4M | $-1.58 |
| Q3 2024 | $2.0K | -$1.3M | $-0.03 |
| Q2 2024 | $3.2K | -$1.7M | $-0.16 |
| Q1 2024 | $3.2K | -$1.4M | $-0.13 |
| Q3 2023 | $2.0K | -$1.2M | $-0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HeartSciences Inc. Dividends, Buybacks & Capital Allocation
HSCSW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for HeartSciences Inc. (CIK: 0001468492)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HSCSW
What is the AI rating for HSCSW?
HeartSciences Inc. (HSCSW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HSCSW's key strengths?
Claude: Maintains $3.4M cash position representing 45% of total assets. Zero long-term debt burden with 0.00x debt-to-equity ratio. ChatGPT: Debt-free balance sheet (0.00x D/E). Positive gross margin indicating potential unit economics if scaled.
What are the risks of investing in HSCSW?
Claude: Revenue essentially zero at $4.3K with -76.6% YoY decline indicates business collapse. Operating cash flow of -$5.8M annually creates ~7 month cash runway at current burn rate. ChatGPT: Going-concern risk from sustained negative FCF and thin liquidity. Dilution risk due to likely capital raises to fund operations.
What is HSCSW's revenue and growth?
HeartSciences Inc. reported revenue of $4.3K.
Does HSCSW pay dividends?
HeartSciences Inc. does not currently pay dividends.
Where can I find HSCSW SEC filings?
Official SEC filings for HeartSciences Inc. (CIK: 0001468492) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HSCSW's EPS?
HeartSciences Inc. has a diluted EPS of $-2.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HSCSW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, HeartSciences Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HSCSW stock overvalued or undervalued?
Valuation metrics for HSCSW: ROE of -241.0% (sector avg: 15%), net margin of -147,973.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HSCSW stock in 2026?
Our dual AI analysis gives HeartSciences Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HSCSW's free cash flow?
HeartSciences Inc.'s operating cash flow is $-5.8M, with capital expenditures of $3.6K. FCF margin is -133,218.6%.
How does HSCSW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -147,973.4% (avg: 12%), ROE -241.0% (avg: 15%), current ratio 1.19 (avg: 2).